Cohera Medical, Inc. Receives FDA Approval of First Tissue Adhesive For Internal Use in the U.S.

Located on Pittsburgh’s North Shore, across the Allegheny River from city center, Cohera Medical, Inc. is committed to creating surgical adhesives and sealants that improve patient care and quality of life for all surgical procedures, applications, and specialties. The company has entered the European market with its first product offering, TissuGlu® Surgical Adhesive, which is indicated in the European market for the approximation of tissue layers where subcutaneous dead space exists between the tissue planes in large flap surgical procedures such as abdominoplasty. Cohera’s researchers designed TissuGlu to help surgeons improve outcomes and eliminate the need for surgical drains in a wide range of surgical procedures. TissuGlu Surgical Adhesive is resorbable, biocompatible for internal use, uses no human or animal-based ingredients, and forms a strong bond between tissues.

On January 6, 2015, Cohera Medical announced that it received a letter from the U.S. Food and Drug Administration that the pending Premarket Approval Application for TissuGlu® Surgical Adhesive is approvable. This is a milestone for the company and another step toward making the product available to surgeons and patients throughout the U.S. Upon approval, it will be the first internal surgical adhesive of its kind approved in this country.